Ask The Board

1. What Should Be Done By Engineers Toward Developing New Methods And Approaches For Process Development And Facility Design To Make The Wide Range Of New Products Faster And Cheaper?
   8/30/2019

   See the answer from Charlene Banard, former head of quality, technical operations at Shire.

2. What Are The Critical Components Necessary When Attempting To Attract An Angel Investor To Your Biopharma Startup?
   8/30/2019

   See the answer from Martin Lehr, CEO and cofounder at Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing novel medicines for hormone receptor positive cancers.

3. What Are The Critical Components Necessary When Attempting To Attract An Angel Investor To Your Biopharmaceutical Startup?
   8/30/2019

   See the answer from Dennis Purcell, a founder and senior advisor of Aisling Capital, who has completed over 200 transactions and supervised over $15 billion life science industry financing and advisory assignments.

4. How Do You View The Integration Of Clinical Research With Clinical Care, And What Approaches Align To Make Clinical Trials Potential Care Options?
   8/1/2019

   See the answer from Kenneth Moch, president and CEO of Cognition Therapeutics.

5. What Are The Most Influential Consortia?
   8/1/2019

   See the answer from Stephen Rapundalo, Ph.D., president and CEO of MichBio.

6. When Is The Best Time For A Scientist To Transition Into A Life Science Leader?
   8/1/2019

   See the answer from Francois Nader, MD, MBA, chairman of Acceleron Pharma.

7. It Seems The High Cost Of Drug Development Is Unsustainable. Should New Regulatory Pathways Be Considered?
   7/1/2019

   See the answer from Tom DiLenge, president, advocacy, law & public policy division for the Biotechnology Innovation Organziation (BIO).

8. What Is Your Opinion On The Present Reimbursement Landscape In U.S. Healthcare?
   7/1/2019

   See the answer from Paul Hastings, CEO of Nkarta Therapeutics. He has over 30 years of biopharmaceutical industry experience.

9. How Can We Ensure We Don't Overburden Patients With Requests For Input Into Our Trial Designs And Disease Burden Questions?
   7/1/2019

   See the answer from Margaret Anderson, a managing director at Deloitte. She was previously Executive Director at FasterCures, a center of the Milken Institute.

10. How Do You Mitigate The Risks To Patient Safety And Data Integrity In Virtual Clinical Trials?
    5/31/2019

    See the answer from Al Altomari, chairman and CEO of Agile Therapeutics.